NOVARTIND · Evonile Pharma Ltd · Biotechnology & Drugs
NOVARTIND · Evonile Pharma Ltd · Biotechnology & Drugs
₹1,713.6+0.2%
As of 05 Nov close
52-week range. Price history incomplete · as of 05 Nov 2026
Price chartDaily closes on the stock page.
Stock Condition:Pro
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue growth acceleratingOperating margin above its own average
Revenue (latest Q)
₹104 Cr
Revenue YoY
PAT YoY
+16.6%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
6.6
P/S (TTM)
15.9
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| NOVARTIND (this stock) | 36.2 | 6.6 | +26.4% | +11.9% | 0 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
0.72% (+0.03pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- unknownbusiness-standard.com· 10 Sept 2026, 10:56 amNovartis India zooms 51% in 3 days; what's driving the pharma stock?
- unknownthehindubusinessline.com· 09 Sept 2026, 09:28 pmNovartis-Pfizer trademark deal has opposite impact on their stock prices; Novartis India jumps 20% while Pfizer slips 3%
- lowbusiness-standard.com· 07 Sept 2026, 06:05 amInnovative ecosystem will make India attractive: Judith Love & Amitabh Dube
- lowthehindubusinessline.com· 20 Aug 2026, 05:52 pmNSE said to plan allowing its shares to trade on own platform
- mediumcorporate actionthehindubusinessline.com· 30 Jul 2026, 08:51 amPE firm ChrysCapital acquires Swiss parent’s stake in Novartis India
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
Governance disclosures
AI-generatedNo governance disclosures identified in NOVARTIND's filed documents yet.